Open main menu

Psychiatrienet β

Moclobemide-hypericum

Revision as of 12:18, 14 October 2015 by Anoek (talk | contribs)
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from moclobemide to hypericum.[1] [2]

Nietinrijdenbord.png Stop moclobemide
  • Before day 1: gradually decrease the dosage of moclobemide to a maximum of 300 mg/day.
  • Day 1: reduce dosage of moclobemide to 150 mg/day.
  • Day 8: stop administration of moclobemide.
Eenrichtingbord.png Start hypericum
  • Day 8-10: a wash-out period of two days is necessary.
  • Day 11: start hypericum after this period in a dosage of 300 mg three times a day (900 mg/day).
Infobord.png More information
  • Occurence of the serotonin syndrome is theoretically possible if no wash-out period is applied.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.